Literature DB >> 23381353

[Efficacy and safety of administration of low-dose unfractionated heparin (LDUH) for the prevention of pulmonary thromboembolism after surgery for lung cancer; the long term outcome].

Masashi Muraoka1, Kouji Mochinaga, Hideyori Sengyoku, Chusei Ryu, Yasushi Ikuta, Satoshi Tabuchi, Ayako Satou, Eiko Inamasu, Shuichi Tobinaga, Hideaki Komatsu, Hiroyuki Yamaguchi, Kouji Kimino.   

Abstract

We evaluated the efficacy and safety of the administration of low-dose unfractionated heparin(LDUH)for the prevention of pulmonary thromboembolism after lung cancer surgery. We operated on 206 patients with primary lung cancer for 8 years;128 males and 78 females, mean age:69.9±8.8 years. All patients were administrated LDUH 5,000 units every 12 hours from the operation day until the day when the patient could walk around the floor. No patients suffered from clinical pulmonary thromboembolism in this period. The duration of treatment was 4.6±2.6 days and the chest tube duration was 5.4±3.0 days. We experienced post-operative intra-thoracic bleeding in 2 patients during the previous 4 years. Based on this experience, we introduced new eligibility criteria;we discontinued LDUH administration on the operation day if diffuse adhesion in the thoracic cavity was observed at operation or intraoperative blood loss was over 500 ml. The dose of LDUH was decreased to 2,500 unit every 12 hours if the postoperative bleeding was over 400 ml on the operation day or the patient's body weight was less than 40 kg. After introduction of the new criteria, no severe bleeding complications occurred during the latter 4 years.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23381353

Source DB:  PubMed          Journal:  Kyobu Geka        ISSN: 0021-5252


  1 in total

Review 1.  Lung Cancer and Pulmonary Embolism: What Is the Relationship? A Review.

Authors:  Yupeng Li; Yu Shang; Wenwen Wang; Shangwei Ning; Hong Chen
Journal:  J Cancer       Date:  2018-08-06       Impact factor: 4.207

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.